AbCellera Biologics Inc. Common Shares (ABCL) is a publicly traded Healthcare sector company. As of May 21, 2026, ABCL trades at $4.54 with a market cap of $1.27B and a P/E ratio of -9.37. ABCL moved +12.72% today. Year to date, ABCL is +33.24%; over the trailing twelve months it is +118.66%. Its 52-week range spans $1.89 to $6.52. Analyst consensus is strong buy with an average price target of $8.75. Rallies surfaces ABCL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ABCL financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ABCL recently traded at $4.54. Market cap is $1.27B. P/E ratio is -9.37. Revenue is $79.21M.
| Metric | Value |
|---|---|
| Price | $4.54 |
| Market Cap | $1.27B |
| P/E Ratio | -9.37 |
| EPS | $-0.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.52 |
| 52-Week Low | $1.89 |
| Volume | 115.64K |
| Avg Volume | 0 |
| Revenue (TTM) | $79.21M |
| Net Income | $-143.96M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $75.13M | $-146.41M | $-0.49 |
| 2023 | $38.02M | $-146.40M | $-0.51 |
| 2022 | $485.42M | $158.52M | $0.56 |
| 2021 | $375.20M | $153.46M | $0.56 |
6 analysts cover ABCL: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.75.